Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 4Recruiting 3Terminated 2Unknown 1No longer available 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3lanreotide 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Octreotide 2Magnetic Resonance Spectroscopy 2Filgrastim 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1folfirinox 1famitinib 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × surufatinib × NET × Clear all
NCT04579679 2025-07-25

Open-Label Surufatinib in European Patients With NET

Hutchmed

Phase 2 Terminated
78 enrolled 20 charts
EndocrineNET

Neuroendocrine Tumors

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡